Efficacy of Isradipine in Early-Stage Parkinson Disease
Researchers assessed the effect of isradipine on clinical progression in previously untreated patients with early-stage PD.
Treatments
Epidiolex Gets Priority Review for Tuberous Sclerosis Complex-Associated Seizures
The FDA has accepted for Priority Review the supplemental New Drug Application for Epidiolex.
Significant Reduction in Monthly Migraine Days Observed With Rimegepant in Prevention Trial
Biohaven announced positive topline results from a pivotal phase 2/3 study evaluating rimegepant for the preventive treatment of episodic and chronic migraine in adults.
Cannabidiol as an Adjunctive Therapy for Patients With Treatment-Resistant Dravet Syndrome
Investigators assessed the efficacy and safety of 2 daily doses of cannabidiol, 10 mg/kg or 20 mg/kg, in children with Dravet syndrome.
Oral Therapy Ozanimod Approved for Relapsing Forms of Multiple Sclerosis
The mechanism by which it exerts therapeutic effects in MS is unknown but may involve the reduction of lymphocyte migration into the central nervous system.
Gene Therapy for Frontotemporal Dementia With a GRN Mutation Gets Fast Track Status
The FDA has granted Fast Track designation to PR006 (Prevail Therapeutics), an experimental gene therapy, to slow the progression of frontotemporal dementia with a GRN mutation.
Telmisartan Adjunct Treatment May Reduce CNS Inflammation During Acute HIV
Telmisartan did not affect biomarkers of central nervous system inflammation or injury when used as an adjunct to ART for acute HIV infection.
Ponesimod NDA for Relapsing Multiple Sclerosis Submitted for Review
The New Drug Application for ponesimod has been submitted to the Food and Drug Administration for the treatment of relapsing multiple sclerosis.
Age of Onset May Affect Clinical Outcomes for Patients With Multiple Sclerosis on DMT
Age-dependent differences seen for clinical outcomes in response to disease-modifying therapy.
Reperfusion Outcomes in Stroke Patients Treated With Idarucizumab
Treatment with idarucizumab can safely facilitate stroke thrombolysis in dabigatran-treated patients, with similar outcomes as patients who did not require idarucizumab therapy.
